Breaking news28 May 2019 11:28
TORTOLA, British Virgin Islands--(BUSINESS WIRE)--Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and increase human longevity, is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.
Souvien is founded on the pioneering research of Professor Li-Huei Tsai, the director of The Picower Institute for Learning and Memory at MIT, and Associate Professor Stephen Haggarty, the director of the Chemical Neurobiology Laboratory at Harvard Medical School/Massachusetts General Hospital, on the epigenetic underpinnings of neurodegeneration.
Professor Tsai said: “We have collected a substantial body of data implicating a critical epigenetic regulator of cellular aging in neurodegeneration. We are delighted to establish this new venture with Juvenescence and their experienced team of proven drug developers.”
“I’m excited to join forces with Juvenescence and their partners as we develop unprecedented therapies from the bench into the clinic,” said Dr. Haggarty.
Juvenescence is also pleased to announce two high level appointments to Souvien: Dr. Jeffrey Sprouse as CEO and Professor Howard Federoff as Chair. Dr. Sprouse has over 25 years of drug discovery experience, having led preclinical programs at both Pfizer and Lundbeck. Professor Federoff is an internationally renowned clinical researcher and former CEO of the UCI Health System.
Sign In
Follow the stocks
